Evidence map›Paper›PMID 40961336›Full record

ArticleChembiochem : a European journal of chemical biology2025

Enantiocomplementary Bioreduction of Flexible Ring N-(3-Oxobutyl)Heterocycles Providing Enantiopure Chiral Fragments for Drug Discovery.

Máté Gergő Honvári, Levente András Mócza, Bence Attila Kucsinka, Pál Csuka, Viktória Bódai, Diana Maria Scrob, László Poppe, Gábor Hornyánszky

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Máté Gergő HonváriDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, Budapest, H-1111, Hungary.
Levente András MóczaDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, Budapest, H-1111, Hungary.
Bence Attila KucsinkaDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, Budapest, H-1111, Hungary.
Pál CsukaDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, Budapest, H-1111, Hungary.ORCID https://orcid.org/0000-0003-3817-376X
Viktória BódaiFermentia Microbiological Ltd, Berlini út 47-49, Budapest, H-1049, Hungary.ORCID https://orcid.org/0000-0002-1870-7552
Diana Maria ScrobBiocatalysis and Biotransformation Research Centre, Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University of Cluj-Napoca, Arany János str. 11., Cluj-Napoca, RO-400028, Romania.
László PoppeDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, Budapest, H-1111, Hungary.ORCID https://orcid.org/0000-0002-8358-1378
Gábor HornyánszkyDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, Budapest, H-1111, Hungary.ORCID https://orcid.org/0000-0001-7895-9711

Funding

Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund (NRDI), European Union, RRF-2.3.1-21-2022-00015Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund (NRDI), European Union, SNN-146370National Authority for Scientific Research and Innovation (Romania), European Regional Development Fund (NextGenerationEU), RENZI call: PNRR-III-C9-2023-I8National Authority for Scientific Research and Innovation (Romania), European Regional Development Fund (NextGenerationEU), RENZI code: 87/31.07.2023
6 · The paper itself

Abstract

In this study, the bioreduction of prochiral N-(3-oxobutyl)heterocycles comprising various (partially) saturated, flexible rings is explored using microbial whole-cell ketoreductases such as wild-type yeast strains including baker's yeast (Saccharomyces cerevisiae) and Escherichia coli cells expressing two enantiocomplementary recombinant alcohol dehydrogenases. Initially, four wild-type yeast strains are screened for ketoreductase activity on a series of nine flexible N-heterocycles with prochiral carbonyl group in the N-(3-oxobutyl) sidechain. The yeast strains resulted in the corresponding (S)-alcohols with a low to moderate conversions. Using recombinant alcohol dehydrogenase whole-cell preparations as biocatalysts ((S)-selective ADH from Rhodococcus aetherivorans (RaADH) and (R)-selective ADH from Lactobacillus kefir (LkADH)) resulted in higher conversions in most cases, while maintaining the full enantiotopic selectivity. Usually, the preparative-scale bioreductions showed comparable or even higher conversions than those observed in the small-scale screening reactions, resulting in virtually enantiopure (S)- and (R)-alcohols (ee > 99%), which are promising chiral fragments with a high degree of drug-likeness. Docking studies confirmed the absolute configuration of the forming (S)- and (R)-alcohols.

Indexed as

Drug DiscoveryHeterocyclic CompoundsAlcohol DehydrogenaseBiocatalysisEscherichia coliLactobacillusOxidation-ReductionRecombinant ProteinsRhodococcusSaccharomyces cerevisiaeStereoisomerismAlcohol DehydrogenaseHeterocyclic CompoundsRecombinant Proteinsalcohol dehydrogenaseenantiocomplementaryketoreductaseswhole‐cell bioreductionyeast

Identifiers

PMID40961336
PMCPMC12498191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.